MRA announces the addition of a new, comprehensive pharmacy program for Bacillus Calmette Guerin (BCG) compounding for Bladder Cancer Therapy

This state of the art program will complement the existing USP <797> and <800> services currently offered by MRA with emphasis on:

  • TICE® / TheraCys® BCG Mycobacterium bovis specific sampling and detection for air and surfaces in addition to existing USP <797> monitoring for viable particulates.
  • Personalized education and proficiency testing specifically designed for BCG compounding pharmacy personnel which includes organism handling and storage, aseptic technique and appropriate biohazard personal protective equipment (PPE).